Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

RJ Motzer; Rini BI; DF Mcdermont; PL Kellokumpu-Lehtinen

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

RJ Motzer
, Rini BI
, DF Mcdermont
, PL Kellokumpu-Lehtinen

Research output: Contribution to journal › Article › Scientific › peer-review

706 Citations (Scopus)

Original language	English
Pages (from-to)	1370-1385
Journal	The Lancet Oncology
Volume	20
Issue number	10
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publication forum classification

Publication forum level 3

Access to Document

https://pubmed.ncbi.nlm.nih.gov/31427204

Cite this

@article{6037aa8b25114d55bf12c8080cc693f2,

title = "Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.",

author = "RJ Motzer and Rini BI and DF Mcdermont and PL Kellokumpu-Lehtinen",

year = "2019",

language = "English",

volume = "20",

pages = "1370--1385",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "10",

}

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. / Motzer, RJ; BI, Rini; Mcdermont, DF et al.
In: The Lancet Oncology, Vol. 20, No. 10, 2019, p. 1370-1385.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

AU - Motzer, RJ

AU - BI, Rini

AU - Mcdermont, DF

AU - Kellokumpu-Lehtinen, PL

PY - 2019

Y1 - 2019

M3 - Article

SN - 1470-2045

VL - 20

SP - 1370

EP - 1385

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 10

ER -